FOR RESEARCH USE ONLY
Constituent evidence onlyPerformance research

CJC-1295 / Ipamorelin

Synergistic GHRH + GHRP blend studied for pulsatile endogenous GH support.

01GH pulsatility02Secretagogue signalling03IGF-1 axis
Molecular signature / cjc-1295-ipamorelin
Structural identity

Dual secretagogue combination: GHRH analogue and GHS-R1a agonist

Also known as

CJC-1295 without DAC + Ipamorelin · GHRH / GHRP combination

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

A pre-mixed blend of CJC-1295 (without DAC) and Ipamorelin, each at 5mg per vial. The two compounds act on complementary axes — GHRH and ghrelin/GHS-R1a — producing a dual-pathway synergistic GH pulse significantly larger than either compound alone, with minimal cortisol or prolactin impact.

The research question

This combination is studied because GHRH and ghrelin-receptor signalling converge on growth hormone release through complementary mechanisms. Research design must account for pulsatility, timing and the distinction between CJC-1295 with and without DAC.

Section 02

Mechanism & research themes

CJC-1295 (no DAC) is a stabilised GHRH analogue that binds pituitary GHRH receptors to stimulate GH synthesis. Ipamorelin is a selective pentapeptide ghrelin/GHS-R1a agonist that triggers acute GH pulses with high receptor specificity.

01

Synergistic GH pulse amplitude greater than either compound alone

02

Improved body composition (reduced adipose, increased lean mass)

03

Recovery and collagen turnover via downstream IGF-1 elevation

04

Improved slow-wave sleep architecture in research subjects

05

Improved lipid panel and insulin-sensitivity markers (GH-deficient studies)

06

Restored youthful GH pulsatility without HGH-style axis suppression

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Constituent evidence only

The two pathways are supported by separate secretagogue research, but this exact preparation has not been validated as a single clinical intervention. Combination claims remain extrapolations.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 100–200mcg CJC-1295 (no DAC) plus 100–300mcg Ipamorelin per injection, once daily 30–60 minutes pre-sleep to align with the natural nocturnal GH pulse. Cycles typically run 8–12 weeks on / 4 weeks off.

Reported persistence

CJC-1295 (no DAC): approximately 30 minutes. Ipamorelin: approximately 2 hours.

Calculator starting point

0.3 mg per reference dose

7 doses per week · 10-week cycle

3 mL default reconstitution volume

Once daily 30–60 min pre-sleep; 8–12 weeks on / 4 weeks off.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate CJC-1295 / Ipamorelin
Section 05

Laboratory handling

Reconstitution reference

For a 5mg / 5mg combination vial, 2mL bacteriostatic water gives 2.5mg/mL of each constituent (5mg/mL combined). For a 10mg / 10mg vial, 4mL gives the same per-constituent concentration. Swirl gently.

Storage reference

Lyophilised: 2–8°C (stable up to 24 months frozen). Reconstituted: 2–8°C, protect from light and heat, use within 28–30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Mild water retention or peripheral oedema can occur, particularly at higher doses — typically dose-dependent.

L2

Injection-site reactions (redness, itching, transient swelling) are common with SC peptide administration.

L3

Chronic IGF-1 elevation should be monitored; sustained supraphysiological dosing carries acromegaly-style risk.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only